Paradigm Biopharma - Adapted therapies to meet unmet demand
Paradigm Biopharmaceuticals is a late-stage Australian drug developer focused on developing injectable pentosan polysulfate sodium (PPS). The company’s most advanced clinical programme is investigating injectable PPS (iPPS, Zilosul) as a potentially disease modifying treatment for knee osteoarthritis (kOA), a globally prevalent condition with unmet medical needs. We believe Paradigm’s comprehensive Phase III programme is designed to maximise the potential of iPPS in kOA. The company is also investigating the use of iPPS in mucopolysaccharidosis (MPS) types I and VI, rare genetic diseases. At end-September 2022, the company had A$92.4m in cash, supported by an August 2022 capital raise of A$66.0m, which management expects will provide a runway into Q124. Additional cash will be needed to fund the final part of the Phase III programme.
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
- Paradigm Biopharma - Adapted therapies to meet unmet demand14 Dec 2022